Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial   Positive high-level results from the TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (..
Plus Therapeutics, a clinical-stage pharmaceutical company, announced positive interim updates from its ReSPECT™ clinical trials at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting. The ReSPECT-GBM Phase 1 trial showed safety and overall survival correlation with absorbed radiation dose in recurrent glioblastoma patients. The ReSPECT-LM Phase 1/Part A trial demonstrated..
Delta-Fly Pharma Inc. has announced the schedule for the interim analysis of the Phase 3 study of DFP-10917 in relapsed/refractory acute myeloid leukemia (R/R AML) patients. The interim analysis will be based on outcome measurements including complete remission rate, overall survival, and safety. The first data processing is scheduled to be completed in mid-July 2023, followed by the second data..
Oncolytics Biotech has announced that its drug, pelareorep, has been selected for inclusion in Precision PromiseSM, a Phase 3 clinical trial designed to evaluate the drug in combination with checkpoint inhibitors and chemotherapeutic agents gemcitabine and nab-paclitaxel. The trial is expected to support approval of the studied combination as a treatment for first-line metastatic pancreatic duct..
